New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2013
09:09 EDTBAXCHMP recommends granting extensions of indications to 2 Baxter vaccines
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Vepacel. The marketing authorization holder for this medicinal product is Baxter Innovations GmbH. The CHMP adopted a new indication as follows2: "Active immunisation against H5N1 subtype of influenza A virus. This indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with H5N1 subtype strains. VEPACEL should be used in accordance with Official guidance". The CHMP also adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Pandemic Influenza Vaccine H5N1 Baxter. The CHMP adopted a new indication to include children and adolescents from the age of 6 months onwards. The full indication for Pandemic Influenza Vaccine H5N1 Baxter will be as follows: “Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.”
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
09:24 EDTBAXBaxter: 1Q16 should be weakest quarter of FY16
Subscribe for More Information
08:53 EDTBAXBaxter sees FY16 CapEx $900M
Says does not anticipate any sales in 2016 in IPS. Sees FY16 surgical franchise sales growth 2%-3%. Sees FY16 renal business sales growth roughly 3%. Sees FY16 operating margin roughly 11%. Sees FY16 interest expense roughly $90M. Sees FY16 adjusted tax rate 19%-20%. Sees FY16 average share count roughly 540M shares. Sees FY16 CapEx $900M. Sees FY16 free cash flow $500M. Sees FY16 operating cash flow roughly $1.4B. Guidance taken from Q4 earnings conference call.
07:04 EDTBAXBaxter sees FY16 EPS ex-items $1.46-$1.54, consensus $1.42
Subscribe for More Information
07:03 EDTBAXBaxter sees Q1 EPS ex-items 28c-30c, consensus 32c
Subscribe for More Information
07:02 EDTBAXBaxter reports Q4 adjusted EPS 43c, consensus 32c
Subscribe for More Information
February 1, 2016
14:32 EDTBAXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
08:09 EDTBAXOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
January 29, 2016
12:25 EDTBAXBaxter volatility elevated into Q4 and outlook
Subscribe for More Information
January 26, 2016
17:31 EDTBAXBaxter initiates voluntary nationwide recall of select lots of IV solutions
Subscribe for More Information
16:21 EDTBAXBaxalta files to sell $1.45B of common stock for holders
Baxalta (BXLT) announced the commencement of an underwritten public offering of approximately $1.45B of its common stock previously issued to and currently owned by Baxter International (BAX), Baxalta's former parent company. J.P. Morgan Securities is acting as the sole underwriter for the offering.
January 25, 2016
17:16 EDTBAXMMS exploring sale of acute care unit, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use